An Act to amend 961.385 (2) (cs) 1., 961.385 (5) (b) and 961.385 (6) (a) of the statutes; Relating to: the prescription drug monitoring program. (FE)
Summary
SB68 extends several sunset dates in Wisconsin’s prescription drug monitoring program (PDMP) law. The bill changes existing statutory provisions in section 961.385 so that requirements related to reviewing a patient’s PDMP records before issuing a prescription, as well as related board review provisions, remain in effect until 2030 instead of expiring in 2025. In practical terms, it preserves the state’s current opioid- and controlled-substance monitoring framework for an additional five years.
The bill does not create a new program or expand the scope of the PDMP; rather, it prevents key parts of the current law from lapsing. By extending the expiration dates, it keeps in place the obligations on practitioners and the related oversight mechanisms that support prescription review and monitoring of controlled substance prescribing. The act became effective upon publication as Wisconsin Act 5.
Impact
SB68 amends Wisconsin Statutes section 961.385 by moving the sunset dates for specified PDMP provisions from 2025 to 2030. This affects practitioners who prescribe controlled substances, their agents who may perform record reviews under applicable standards of practice, and the state board functions tied to PDMP review results. The bill preserves existing statutory requirements and administrative oversight rather than altering the substantive operation of the program.
Sentiment
The available record shows no committee transcripts or recorded votes, so there is no documented debate or roll-call sentiment in the provided materials. Based on the bill’s content, the measure appears to be a routine continuation of an existing public-safety and prescription-monitoring policy, with no visible evidence of controversy in the supplied context.
Contention
No specific points of contention are documented in the provided transcripts or vote history. The only notable policy issue apparent from the text is whether the PDMP requirements should continue beyond their current sunset dates, but the materials do not identify any legislators, stakeholders, or interest groups opposing or supporting the extension.
Crossfiled
An Act to amend 961.385 (2) (cs) 1., 961.385 (5) (b) and 961.385 (6) (a) of the statutes; Relating to: the prescription drug monitoring program. (FE)